medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2006, Number 2

<< Back Next >>

Rev Invest Clin 2006; 58 (2)

Safety of the blood supply in Mexico from 1999 to 2003

Vázquez-Flores JA, Valiente-Banuet L, Marín LRA, Sánchez-Guerrero SA

Language: Spanish
References: 17
Page: 101-108
PDF size: 81.83 Kb.


ABSTRACT

Introduction. The incidence of the infection by the viruses of the human immunodeficiency (HIV), hepatitis B (HBV) and hepatitis C (HCV) has diminished enormously in developed countries during the last 20 years; nevertheless, in our country we do not know such an incidence and, therefore, the safety of our blood supply. Material and methods. We performed a retrospective analysis at the Centro Nacional de la Transfusión Sanguínea (CNTS) assessing 17,176,298 serologic tests including HIV, HCV and HBV carried on 5,725,432 blood units collected and informed to the CNTS from January 1999 to December 2003 by all the Mexican blood banks. Prevalence, incidence and residual risk of each one of the aforementioned serologic markers were calculated. Results. The five years mean prevalence for HIV, HBV and HCV has remained steady. The residual risk (RR) when hemagglutination test was employed was 1:977 for HCV; 1:1,564 for HBV and 1:1,262 for HIV. Whereas the RR when ELISA was performed decreased to 1:2,781 for HCV; 1:3,185 for HBV and 1:9,969 for HIV. If nucleic acid amplification test were employed, RR would be 1:8,170 for HBV; 1:9,915 for HCV and 1:19,939 for HIV. Conclusions. The theoretical risk for transfusion transmitted diseases in our country is still worrisome.


REFERENCES

  1. Goodnough LT, Shander A, Brecher ME. Transfusion medicine: looking to the future. Lancet 2003; 361: 161-9.

  2. Programa de Acción: Transfusión sanguínea. Secretaría de Salud. 1a. Ed. 2002. México. ISBN 970-721-042-7.

  3. Dodd RY, Notari EP, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in American Red Cross blood donor population. Transfusion 2002; 42: 975-9.

  4. Kleinman S, Busch MP, Korelitz JJ, et al. The incidence/window period model and its use to assess the risk of transfusiontransmitted human immunodeficiency virus and hepatitis C virus infection. Transfus Med 1997; 11: 155-72.

  5. AuBuchon JP, Birkmeyer JD, Busch MP. Safety of the blood supply in the United States: oportunities and controversies. Ann Intern Med 1997; 127: 904-9.

  6. Busch MP. Closing the window on viral transmission by blood transfusion. In: Stramer SL (ed.). Blood safety in the new millennium. 1st. Ed. Bethesda: American Association of Blood Banks; 2001, p. 33-54.

  7. Ruth WK, Weber M, Seifried E. Feasibility and efficacy of routine PCR screening of blood donations for hepatitis C virus, hepatitis B virus and HIV-1 in a blood bank setting. Lancet 1999; 353: 359-63.

  8. Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP. Transfusion medicine: first of two parts: blood transfusion. N Engl J Med 1999; 340: 438-47.

  9. American Society of Hematology. Education program book. San Diego, California. December 6-9, 2003: 577.

  10. Norma Oficial Mexicana NOM-003-SSA2-1993 para la recolección y manejo de sangre humana y sus componentes con fines terapéuticos. México, 1993.

  11. Marin RA, Romero S, Infante L, et al. Hepatitis C seroprevalence in accepted versus deferred blood-donor candidates evaluated by medical history and self-exclusion form. Tansfusion 2004; 44: 1344-9.

  12. Modificación de la Ley General de Salud. Diario Oficial de la Federación. 30 de junio de 2003.

  13. Sánchez-Guerrero SA, Romero-Estrella S, Rodríguez A, et al. West Nile Virus in the Mexican blood supply. Transfusion 2006; 46: 111-7.

  14. Juárez Rangel E, Vite Casanova MJ, Marín y López RA, et al. Auditoría transfusional retrospectiva en el Centro Nacional de la Transfusión Sanguínea. Rev Invest Clin 2004; 56: 38-42.

  15. Pita L. Cabrera B, Ortega C. Motivos de transfusión de plasma fresco congelado en un hospital general. Rev Invest Clin 1999; 51: 89-92.

  16. Stramer SL, Glynn SA, Kleinman SH, et al. Detection of HIV infections among antibody-negative blood donors by nucleic acid-amplification testing. N Engl J Med 2004; 351: 760-8.

  17. Sibinga CTHS and Murphy MF. Hemovigilance: an approach to risk management in transfusion medicine. In: Mintz PD (ed.). Transfusion therapy: clinical principles and practice. 2nd Ed. Bethesda: AABB Press; 2005, p. 631-44.




2020     |     www.medigraphic.com